Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Gyre Therapeutics Inc increased its cash reserves by 33.10%, or 8.33m. The company earned 25.89m from its operations for a Cash Flow Margin of 22.82%. In addition the company generated 2.50m cash from financing while 19.76m was spent on investing.
Cash flow per share | -0.5759 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.7056 |
---|---|
Tangible book value per share | 0.7034 |
More ▼
Balance sheet in USDView more
Current ratio | 3.44 |
---|---|
Quick ratio | 3.07 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼